FOXP4 and cancer: We observed that the high FOXP4‐AS1 expression was significantly associated with an unfavorable prognosis in PDAC, and increased risk of cancer‐related death of PDAC patients (adjusted P = .008; adjusted HR = 2.143; 95% CI = 1.221‐3.760).